Bayer AG (ADR) Gets Regulatory Approval For Purchase of Algeta

Bayer, who recently raised its offer price for Algeta, its partner in the development of prostate cancer drug Xofigo, gets German regulatory approval to proceed with deal.

Jan 10, 2014 at 11:29AM

German pharmaceutical company Bayer AG (NASDAQOTH:BAYRY) may soon have a new prostate cancer therapy called Xofigo in its drug pipeline. The Federal Cartel Office, Germany's antitrust authority, approved Bayer's purchase of the drug's co-creator , Norwegian biotech firm Algeta ASA (NASDAQOTH:ALGZF). Since 2009, Bayer and Algeta have been working together to develop Xofigo .

Algeta's board of directors had already given its blessing to a takeover bid made by the German drugmaker for $2.87 billion. The board urged shareholders to accept Bayer's offer of $59.20 a share, a higher offer than a bid made by the company last month. The offer price is 37% higher than Algeta's share value prior to the Nov. 25 perliminary bid .

Algeta's Chairman Stein Holst Annexstad stated that the offer is in line with the value of the company and provides shareholders with a substantial cash premium. The offer, which represents 14% of Algeta's outstanding shares, will be considered final once 90% of shareholders agree with the buyout .

Drug expected to strengthen Bayer's oncology unit

Xofigo received FDA approval in May 2013; in Europe, it was approved this past November. It's considered one of Bayer's top five new pharmaceutical products. The drug is a form of radiation treatment and an alternative to chemotherapy and meant for use by patients whose prostate cancer has spread to their bones. Bayer considers the drug a blockbuster – sales in the third quarter were $17 million and could reach $7.5 billion annually .

The acquisition of Algeta would boost Bayer's oncology segment, which currently has several cancer therapies that are in their early stages of development. For fiscal 2013's third quarter, the company reported sales of Xofigo of about $16 million . Bayer has high expectations for Xofigo, which is currently awaiting approval for use in earlier-stage cancer patients, and in other areas, like breast cancer.

The current arrangement between Bayer and Algeta involves both companies marketing the drug and splitting its sales 50-50  . Bayer has also shown interest in the development of Algeta's Thorium-227, which has found success as a new-targeted cancer therapy.

Acquisition presents opportunity to expand cancer therapies

By acquiring Algeta and majority control over Xofigo and the biotech's future cancer treatments, Bayer can expand its pipeline of innovative cancer therapies. Roche (NASDAQOTH:RHHBY), and its wholly owned subsidiary Genentech, have found considerable success with its extensive line of cancer treatments.

For the first nine months of 2013, Roche reported higher sales of 7% in its pharmaceuticals division, in part due to strong demand for several of Roche's cancer treatments. Sales of Avastin, used to treat ovarian cancer, rose an average of 13% across all markets.

New drugs Perjecta and Kadcyla, which treat breast cancer, were both launched last year. According to Roche's 2013 nine-month report, Perjecta has been well received by oncologists and has sold well in the U.S., Germany, and Switzerland. The drug has become the "new standard of care" for HER2-positive metastatic breast cancer, a more aggressive and fast-growing type of cancer. Kadcyla is the first antibody-drug conjugate approved to treat HER2-positive breast cancer. The drug is a new type of cancer therapy that specifically targets cancer cells and has fewer side effects .

My Foolish conclusion

If 90% of Algeta's shareholders agree to the deal, Bayer's takeover of the company could close by the first quarter of 2014. Bayer's higher offer for the company is no surprise given that Algeta's shares have rise about 100% throughout 2013. The acquisition should help Bayer expand its business and profit from the newer cancer treatments that are hitting the market.

Game-Changing Biotechs To Watch Today

The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Eileen Rojas has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers